SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 20, 2010
EFT BIOTECH HOLDINGS, INC.
------------------------------------------
(Name of Small Business Issuer in its charter)
Nevada 0-53730 20-1211204
------------------------ --------------------- -------------------
(State of incorporation) (Commission File No.) (IRS Employer
Identification No.)
17800 Castleton St., Suite 300
City of Industry, CA 91748
---------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (626) 581-3335
N/A
-------------------------------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain officers; Compensatory Arrangements of Certain Officers.
On September 20, 2010 Jack Jie Qin was appointed as the Company's principal
accounting officer. Mr. Qin is the Company's president and principal executive
and financial officer. Information regarding Mr. Qin can be found in the
Company's report on form 10-K for the year ended March 31, 2010. The Company's
10-K report is available to the public through the website of the Securities
Exchange Commission (www.sec.gov).
Item 8.01 Other Events.
Between January and August of 2008 the Company sold 14,890,040 Units to
non-U.S. residents at a price of $3.80 per Unit. The Units were sold pursuant to
the exemption provided by Regulation S of the Securities and Exchange
Commission.
Each Unit consisted of one share of the Company's common stock and one
warrant. Each warrant allows the holder to purchase one share of the Company's
common stock at a price of $3.80.
The expiration date of the warrants has been extended to November 30, 2011.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 22, 2010 EFT BIOTECH HOLDINGS, INC.
By: /s/ Jack Jie Qin
-----------------------
Jack Jie Qin, President